Norris Medicines Ltd

Norris Medicines Annual Report

Norris Medicines Limited has filed its 35th Annual Report for the financial year 2025-26, including the notice of its upcoming Annual General Meeting.

Norris Medicines Annual General Meeting

Norris Medicines approved the Directors' Report, Annual Report, and convening of the 35th Annual General Meeting for September 29, 2026.

Norris Medicines Q1 FY27 Results: Net Loss of ₹0.4 Cr, Loss Widens

Norris Medicines Ltd reported revenue from operations of ₹0.9 Cr (-40.0% YoY) and a net loss of ₹0.4 Cr for Q1 FY27.

Key figure

Net loss ₹0.4 Cr

Norris Medicines Board Meeting Date

Norris Medicines Limited has scheduled a board meeting for August 14, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.

Norris Medicines Management Change

Norris Medicines Limited has appointed Mr. Iqubal Ismail Patel as the Chief Financial Officer and Key Managerial Personnel, effective July 30, 2026.

Norris Medicines Other Announcement

Norris Medicines Ltd filed its quarterly shareholding pattern as of June 30, 2026. The document lists promoter and public holdings per Regulation 31.

Norris Medicines Q4 FY26 Results: Turns Profitable, Net Profit ₹0.1 Cr

Norris Medicines Ltd reported revenue from operations of ₹1.4 Cr (-48.1% YoY) and net profit of ₹0.1 Cr for Q4 FY26.

Key figure

Net profit ₹0.1 Cr

Norris Medicines Financial Results

Norris Medicines Limited approved audited financial results for the year ended March 31, 2026. The company also appointed M/s. Dhiren Y Parikh & Co. as Internal Auditors.

Norris Medicines Board Meeting Date

Norris Medicines scheduled a board meeting for May 30, 2026, to approve audited FY26 financial results. The trading window remains closed until 48 hours post-declaration.